Carbidopa Hydrate

SKU: orb1225135

Description

An inhibitor of DOPA decarboxylase, preventing conversion of levodopa to dopamine. It is used in parkinson disease to reduce peripheral adverse effects of levodopa. It has no antiparkinson actions by itself.

Key Properties

• CAS Number: 38821-49-7
• MW: 244.24
• Purity: >98% (HPLC)
• Formula: C₁₀H₁₆N₂O₅
• SMILES: C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O
• Target: Decarboxylase
• Solubility: DMSO: 10 mM

Bioactivity

• In Vivo:
  Carbidopa monohydrate also induces nuclear uptake of the AhR, and In vivo studies show that carbidopa at a dose of 1 mg/mouse significantly inhibits tumor growth in athymic nude mice bearing BχPC3 cells as xenografts.
• In Vitro:
  Carbidopa ((S)-(-)-Carbidopa) monohydrate exhibits activities similar to that described for other AhR ligands in BχPC3 and Capan-2 cells, namely the induction of CYP1A1 and CYP1A2, which are inhibited by AhR antagonists such as CH223191.Carbidopa, a aromatic-L-amino acid decarboxylase inhibitor, is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Carbidopa is lethal (IC50 = 29 μM).

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

Decarboxylase